Photodynamic Blood Product Decontamination

描述(申请人提供)：这项建议的目标是共价固定化全碳纳米颗粒，它是一种优秀的光敏剂(PS)，固定在生物惰性聚合物骨架上，用于光动力灭活血液产品中的病原体。然后，这些聚合物将被放置在可渗透的滤芯中，并固定在流动反应器中。在将血液产品装入反应堆后，液体将循环，并用激光照射光催化剂。发光的PS催化形成单线态氧，1O2*，这是一种活性氧物种，将使血液产品中的病原体失活。然后，去污染的血液产品被简单地从反应堆中移除，留下C60修饰的聚合物。 将研究三种类型的聚合物骨架：1)疏水聚合物，2)聚阳离子聚合物，3)非离子亲水聚合物。用C60修饰聚合物的合成步骤是从商业上可用的聚合物开始的，是简单的文献程序。在光催化剂合成和反应器构建后，病原体灭活系统将在一系列体外实验中进行评估，以确定新系统对血液产品的最佳去污应用。 与传统的均相PS相比，预期有几个优点，例如亚甲基蓝：1)没有后处理毒性，因为光催化剂是异相的并且集成到反应器结构中，并且在完成处理后，血液产物简单地从反应器中移除，留下催化剂；2)由于聚合物骨架相对于血液成分的损伤，预期病原体灭活的选择性增强；3)将使用的纳米PS具有非常高的单线态氧量子产率，高于传统PS 该项目的愿景是将一种新颖、经济的系统引入血液产品市场，用于灭活血液产品中的病原体。

DESCRIPTION (provided by applicant): The objective of this proposal is to covalently immobilize an all-carbon nanoparticle that is an excellent photosensitizer (PS) onto biologically inert polymeric backbones for the photodynamic inactivation of pathogens in blood products. The polymers will then be placed in a permeable cartridge and fixed into a flow-through reactor. After filling the reactor with the blood product, the fluid will be circulated and the photocatalyst illuminated with laser light. The illuminated PS catalyzes the formation of singlet oxygen, 1O2*, a reactive species of oxygen that will inactivate pathogens in the blood product. The decontaminated blood product is then simply removed from the reactor, leaving the C60-modified polymer behind. Three types of polymeric backbones will be investigated: 1) hydrophobic polymer, 2) polycationic polymer, 3) non-ionic hydrophilic polymer. The synthetic steps to modify the polymers with C60 start from commercially available polymers and are simple literature procedures. After photocatalyst synthesis and construction of the reactor, the pathogen inactivation system will be evaluated in a series of in vitro experiments to determine the optimal blood product decontamination applications of the new system. Several advantages are expected over conventional homogeneous PS such as methylene blue: 1) there is no post-treatment toxicity because the photocatalyst is heterogeneous and integrated into the reactor structure and upon completion of treatment, the blood product is simply removed from the reactor leaving the catalyst behind, 2) enhanced selectivity of pathogen inactivation is expected due to the polymeric backbone's tunable affinity relative to damage to blood components 3) the nanoparticle PS that will be used has a very high singlet oxygen quantum yield, higher than conventional PS The vision of this project is to introduce a novel, economical system to the blood product market for the inactivation of pathogens in blood products.